{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:11:33Z","timestamp":1775002293758,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106627","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T21:51:06Z","timestamp":1753048266000},"page":"106627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Delayed access and adherence are real-world challenges that compromises effectiveness of natalizumab in multiple sclerosis"],"prefix":"10.1016","volume":"103","author":[{"given":"Rafael Augusto","family":"Rosalem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Gondim Peixoto","family":"Spricigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateus Boaventura","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarso","family":"Adoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira Lu\u00edsa","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-3763","authenticated-orcid":false,"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106627_bib0001","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1590\/0004-282x-anp-2021-0162","volume":"79","author":"Becker","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106627_bib0002","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3111\/13696998.2014.940422","article-title":"Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis","volume":"17","author":"Bergvall","year":"2014","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2025.106627_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103821","article-title":"Feedback from neurology residents and neuroimmunology fellows about the practical training in multiple sclerosis","volume":"63","author":"Diogo Silva","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106627_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210417","article-title":"A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies","volume":"14","author":"Duquette","year":"2019","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2025.106627_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrd3501","article-title":"Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response","volume":"10","author":"Eichler","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.msard.2025.106627_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241241382","article-title":"Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study","volume":"17","author":"Gold","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106627_bib0007","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1055\/s-0042-1754348","article-title":"Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center\u2019s approach","volume":"80","author":"Gomes","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106627_bib0008","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2014-307591","article-title":"Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis","volume":"85","author":"Gueguen","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106627_bib0009","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106627_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106627_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2018.19271","article-title":"Interventions to improve medication adherence: a review","author":"Kini","year":"2018","journal-title":"JAMa"},{"key":"10.1016\/j.msard.2025.106627_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.11613\/BM.2013.018","article-title":"The Chi-square test of independence","author":"McHugh","year":"2013","journal-title":"Biochem. Med."},{"key":"10.1016\/j.msard.2025.106627_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106627_bib0014","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40120-021-00319-3","article-title":"Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: a retrospective claims analysis","volume":"11","author":"Pardo","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106627_bib0015","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis","volume":"104581","author":"Pipek","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106627_bib0016","first-page":"1","article-title":"The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil","volume":"82","author":"Pipek","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106627_bib0017","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106627_bib0018","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 3","key":"10.1016\/j.msard.2025.106627_bib0019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","article-title":"Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study","volume":"31","author":"Sangalli","year":"2011","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106627_bib0020","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo","volume":"70","author":"Silva","year":"2022","journal-title":"Braz. Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2025.106627_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/ane.13697","article-title":"Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis","author":"Silva","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2025.106627_bib0022","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective Treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106627_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578140","article-title":"Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis","volume":"381","author":"Terrim","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106627_bib0024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106627_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/13524585231199323","article-title":"Misdiagnosis in multiple sclerosis in a Brazilian reference center: clinical, radiological, laboratory profile and failures in the diagnostic process-cohort study","author":"Tieppo","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106627_bib0026","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106627_bib0027","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: are we helping or hurting?","volume":"68","author":"West","year":"2010","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:15:21Z","timestamp":1774998921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"alternative-id":["S2211034825003694"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106627","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed access and adherence are real-world challenges that compromises effectiveness of natalizumab in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106627"}}